Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
Status:
Not yet recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This trial studies the effect of pegloticase in reducing uric acid levels in patients with
hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis
syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the
blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney
function. The goal of this trial is to learn if pegloticase may lower uric acid levels in
blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.